Table 2 Zone of inhibition observed for nalidixic acid derivatives and their relevant nanoformulation against Candida albicans (in mm)
From: Resurrection of Nalidixic Acid: Evaluation of Water-Based Nanoformulations as Potential Nanomedicine
Concentration (μgmL-1) | 800 | 400 | 200 | 100 | 50 |
|---|---|---|---|---|---|
Compound | |||||
1 | 20 ± 2.83 | 19 ± 1.41 | 15 ± 2.83 | 12 ± 1.41 | – |
NF1 | 23 ± 1.41 | 21 ± 2.83 | 20 ± 1.41 | 15 ± 1.41 | 10 ± 2.83 |
2 | 20 ± 1.41 | 20 ± 2.83 | 15 ± 1.41 | 10 ± 4.24 | 05 ± 1.41 |
NF2 | 24 ± 2.83 | 21 ± 2.83 | 15 ± 2.83 | 10 ± 0 | 07 ± 1.41 |
3 | 18 ± 2.83 | 1.5 ± 2.83 | 09 ± 1.41 | – | – |
NF3 | 23 ± 2.83 | 21 ± 1.41 | 15 ± 1.41 | 10 ± 0 | – |
4 | – | – | – | – | – |
NF4 | 06 ± 1.41 | 03 ± 1.41 | – | – | – |
5 | – | – | – | – | – |
NF5 | 03 ± 1.41 | – | – | – | – |
6 | 21 ± 1.41 | 17 ± 2.83 | 14 ± 1.41 | 12 ± 1.41 | 11 ± 1.41 |
NF6 | 24 ± 1.41 | 22 ± 1.41 | 19 ± 1.41 | 17 ± 1.41 | 16 ± 2.83 |
7 | 17 ± 1.41 | 16 ± 1.41 | 13 ± 2.83 | 10 ± 1.41 | 07 ± 1.41 |
NF7 | 20 ± 2.83 | 18 ± 1.41 | 18 ± 2.83 | 15 ± 2.83 | 15 ± 1.41 |
8 | 18 ± 1.41 | 16 ± 1.41 | 12 ± 1.41 | 10 ± 1.41 | 06 ± 1.41 |
NF8 | 20 ± 1.41 | 20 ± 1.41 | 17 ± 1.41 | 16 ± 1.41 | 14 ± 1.41 |
Cycloheximide | – | – | – | – | – |
Nystatin | – | – | – | – | – |
Control | – |